Nouress Generic: When Will Generic Cysteine Be Available?

Dr. Brian Staiger, PharmD, BCPS

This page is aggregated from FDA records, court filings and company announcements. Coded and designed by

Updated October 9, 2026 How we build our data

Nouress Generic at a Glance

Four quick answers from FDA records and our estimate.

  1. When is the first generic expected? March 2039 About 12.5 years away Why then?
  2. Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
  3. When does the last patent end? March 2039 20 patents listed with the FDA
  4. Can you buy a generic today? Not yet No company lists one for sale

Explains

PharmD, BCPS · Clinical pharmacist Updated

Generic cysteine hydrochloride is expected to be available in March 2039, about 12.5 years away. None is for sale yet.

Why March 2039?

It is when Nouress’s patents 10,493,051, 10,543,186 and 11,045,438 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.

Why hasn’t the FDA approved a generic yet?

That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).

Will the generic cost less?

Usually, but no company is recorded as having applied to make one yet, and a single company usually brings only a modest drop. See the price pattern

What should I do now?

Keep taking Nouress as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you

Our month is only an estimate based on available information, so we never name a day.

Nouress by the Numbers

Reason
Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
How sure
Probable More likely than not, but it can still move.
Price competition
None filed yet No filers on record
Brand sales
Sales not reported
  • FDA approved 2019 December 2019 FDA Orange Book
  • Patents listed 20 last runs to March 2039 FDA Orange Book

Nouress’s Road to a Generic

Nouress has had the market to itself since the FDA approved it in December 2019 (Baxter Healthcare Corp). Its 20 listed patents run to March 2039.

The first generic of Nouress is expected in March 2039.

Why that month: patents 10,493,051, 10,543,186 and 11,045,438, on the product’s formulation and a way of using it, end then.

Brand alone on the market Since FDA approval, December 2019
Patent 10,478,453 Expires January 2039
Patent 11,510,941 Expires March 2039
Patent 10,493,051 Expires March 2039 The patent behind the expected month of generic availability
Patent 10,543,186 Expires March 2039 The patent behind the expected month of generic availability
Patent 10,702,490 Expires March 2039
Patent 11,045,438 Expires March 2039 The patent behind the expected month of generic availability
Brand alone on the market Patent on the formulation Patent on a use First generic expected 14 more patents end earlier; every patent is in the table below. Swipe the chart sideways to see every year.

Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.

Nouress Patents and FDA Protections

Every patent and exclusivity the FDA Orange Book lists for Nouress’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.

The one that matters for a generic launch: patents 10,493,051, 10,543,186 and 11,045,438, which end in March 2039, the month the first generic is expected.

Patents listed with the FDA (20)
PatentWhat it coversProtects untilStatus
10,478,453 The product’s formulation; a way of using it (U-2752) January 2039 Active
10,583,155 The product’s formulation; a way of using it (U-2752) January 2039 Active
10,653,719 The product’s formulation January 2039 Active
10,905,713 The product’s formulation January 2039 Active
10,905,714 The product’s formulation January 2039 Active
10,912,795 The product’s formulation January 2039 Active
10,918,662 The product’s formulation January 2039 Active
10,933,089 The product’s formulation January 2039 Active
11,510,942 The product’s formulation; a way of using it (U-2752) January 2039 Active
11,642,370 The product’s formulation January 2039 Active
11,648,262 The product’s formulation January 2039 Active
11,679,125 The product’s formulation January 2039 Active
11,684,636 The product’s formulation January 2039 Active
11,826,383 The product’s formulation January 2039 Active
12,569,514 The product’s formulation January 2039 Active
11,510,941 The product’s formulation March 2039 Active
10,493,051 Sets the expected month of generic availability The product’s formulation March 2039 Active
10,543,186 Sets the expected month of generic availability A way of using it (U-2722) March 2039 Active
10,702,490 The product’s formulation March 2039 Active
11,045,438 Sets the expected month of generic availability The product’s formulation March 2039 Active

Source: FDA Orange Book, application 212535. Patent numbers open the patent on Google Patents.

Who Is Lined Up to Make Generic Cysteine Hydrochloride

Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.

1

Applied to the FDA

No company is recorded as having applied to the FDA to make a generic Nouress yet.

2

Approved by the FDA

Not yet. The FDA has not approved a generic cysteine hydrochloride. Final approval often comes close to the day a generic can be sold.

3

For Sale in Pharmacies

Not yet. No company lists a generic cysteine hydrochloride for sale with the FDA.

Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).

Nouress Price: What Pharmacies Pay and What Generics Usually Do

What a Generic Could Cost

How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Nouress, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).

Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.

Nouress Strengths and Forms

StrengthFormHow it is takenApprovedStatus
500MG/10ML (50MG/ML)SolutionIntravenousDecember 2019Discontinued reference product

Source: FDA Orange Book, Baxter Healthcare Corp.

What a Generic Nouress Means for You

Nothing Changes Until It Is in Pharmacies

Until a generic is actually for sale, keep filling Nouress as usual. When one arrives, there is nothing you need to sign up for.

Your Pharmacy May Switch You Automatically

Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.

It Will Probably Look Different

US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.

Your Insurance May Change Too

Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.

Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Nouress”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.

Ask a pharmacist about Nouress

Questions people ask about Nouress

Is there a generic for Nouress right now?

No. As of October 9, 2026 no generic cysteine hydrochloride is listed for sale in the FDA NDC Directory.

When will Nouress go generic?

March 2039 is the expected month, and that is probable but not certain. It is when Nouress’s patents 10,493,051, 10,543,186 and 11,045,438 end. They cover the product’s formulation and a way of using it, and once they end, generics can go on sale as soon as the FDA approves them.

Will generic cysteine hydrochloride be the same as Nouress?

Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.

How much will the generic cost?

Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.

Has the FDA approved a generic Nouress?

Not yet. The FDA Orange Book lists no approved generic version of Nouress.

When does the Nouress patent expire?

The FDA Orange Book lists 20 patents for Nouress; the last runs to March 2039. The one behind the expected month is patents 10,493,051, 10,543,186 and 11,045,438, which end in March 2039. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (March 2039) weighs all of that.

Changes to This Projection

  • First generic expected March 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.

Every change to the expected month is logged here with the month we saw it.

Also Going Generic

All upcoming generics

About Nouress

Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.